Why UK Paid More to Win Back Pharma
AstraZeneca is restarting a £300 million UK research investment after the UK-US pharmaceutical deal changed the commercial case for launching new medicines in Britain. The short answer to why AstraZeneca is investing in the UK again: Britain has agreed to pay more for prospective new medicines, raise medicine-access thresholds and protect tariff-free pharmaceutical exports to…
